Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma.

Authors: Tanaka, Toshiaki  Kitamura, Hiroshi  Torigoe, Toshihiko  Hirohashi, Yoshihiko  Sato, Eiji  Masumori, Naoya  Sato, Noriyuki  Tsukamoto, Taiji 
Citation: Tanaka T, etal., J Cancer Res Clin Oncol. 2011 May;137(5):789-94. doi: 10.1007/s00432-010-0940-6. Epub 2010 Jul 31.
Pubmed: (View Article at PubMed) PMID:20676679
DOI: Full-text: DOI:10.1007/s00432-010-0940-6

PURPOSE: To verify the efficacy of a serum autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 (PHD3) as a serological marker for RCC.
METHODS: Serum samples and surgically resected tumor tissue specimens were obtained from 22 patients with primary RCC, 15 of whom underwent radical nephrectomy and 7 partial nephrectomy. Preoperative serum samples were obtained just before tumor resection. Postoperative serum samples were obtained from 17 patients at least 1 month after tumor removal. Serum samples were also obtained from 26 healthy volunteers. Titers of the anti-PHD3 antibody (Ab) were determined by enzyme-linked immunosorbent assay.
RESULTS: Serum anti-PHD3 Ab titers were significantly higher in patients with RCC than in healthy volunteers (0.610 ± 0.023 vs. 0.591 ± 0.031, P = 0.0001). Using a cutoff point of 0.599, sensitivity, specificity, and positivity for prediction of RCC were 86.4, 57.7, and 63.3%, respectively. In all 17 patients, titers of serum anti-PHD3 were decreased after the surgical resection compared with those before operation (0.622 ± 0.023 vs. 0.580 ± 0.024, P = 0.0003).
CONCLUSIONS: The present study suggests that the anti-PHD3 Ab may be a novel serological marker for RCC and the titer may reflect the tumor burden in each individual.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 13506732
Created: 2018-02-08
Species: All species
Last Modified: 2018-02-08
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.